EPSTEİN BARR VİRÜSÜ VE BURKİTT LENFOMA

Abstract

Epstein-Barr Virus (EBV) Herpesviridae familyasına ait dünyada yaygın olarak görülen, orofarinks salgıları ile yakın temas, kan ve kontamine eşyalarla bulaşabilen DNA yapılı bir virüstür. EBV enfeksiyonları genel itibariyle ergenlik döneminde gelişmekte ve asemptomatik olarak seyretmektedir. EBV yapısında bulundurduğu Epstein Barr Nükleer Antijenleri (EBNA), Viral kapsid antijeni (VCA) ve Latent membran protein (LMP) ile konakçı hücreyi enfekte edebilen ve enfeksiyon esnasında latent olarak kalabilen güçlü bir virüstür. Doğal şartlarda konakçı da latent halde bulunan EBV, fırsat bulduğu zaman İnfeksiyoz Mononükleoz (IM), Burkitt Lenfoma (BL) gibi ciddi hastalıklara neden olabilmektedir. EBV’nin neden olduğu en riskli ve ciddi hastalık BL’dir. BL, özellikle MYC genlerinin immunoglobulin zincirlerindeki translokasyonu sonucu ortaya çıkmaktadır.    

Keywords

• Epstein Barr Virüsü (EBV),Burkitt Lenfoma (BL),EBNA,VCA

EPSTEİN BARR VİRÜSÜ VE BURKİTT LENFOMA

Öz

References

1. 1. Abdel-Hamid M, Chen J, Constantine N, Massoud M, Raab-Traub N. 1992. EBV strain variation: geographical distribution and relation to disease state. Virology. 190:168–175.
2. 2. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009–20.
3. 3. Brady G, MacArthur GJ, Farrell PJ, 2007. Epstein–Barr virus and Burkitt lymphoma. J Clin Pathol. 60(12): 1397-402.
4. 4. Cai X, Schafer A, Lu S. 2006. Epstein–Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006;2:e23.
5. 5. Cox C, Chang S, Karran L. 1996. Persistent Epstein-Barr virus infection in the common marmoset (Callithrix jacchus). J Gen Virol. 77:1173-1180.
6. 6. Çağlar M,, Balcı Y., Polat A., Cevahir N., Çölgeçen Ş. 2014. Enfeksiyöz mononükleoz tanısı alan hastaların değerlendirilmesi. Pamukkale Tıp Dergisi, (3), 210-213. Retrieved from http://dergipark.gov.tr/patd/issue/35413/393437.
7. 7. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt’s lymphma. Lancet. 703-283:702.
8. 8. Epstein-Barr Virus and Infectious Mononucleosis." Centers for Disease Control.http://www.cdc.gov/ncidod/diseases/ebv.htm. Accessed: 11/3/12.

9. 9. Epstein-Barr Virus." International Agency for Research on Cancer. IARC Monographs. 1997. 49-92. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-6.pdf. Accessed: 11/3/12.
10. 10. Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist 2006;11:375.
11. 11. Fidan I., Yuksel S., İmir T. 2005. Değişik yaş gruplarında Epstein-Barr virus antikorlarının araştırılması. J Infect 2005;19:453-456. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
12. 12. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. 1984 Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 1984; 81(14): 4510–4514.
13. 13. Gruhne B, Sompalle R, Marescotti D, Kamranvar SA, Gastaldello S, Masucci MG. 2009. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. PNAS. 106(7): 2313-2318.
14. 14. Hammerschmidt W, Sugden B. 2004. Epstein–Barr virus sustains Burkitt’s lymphomas and Hodgkin’s disease. Trends Mol Med 6-10:331.
15. 15. Hjalgrim, H., Friborg, J. and Melbye, M., 2007. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. The epidemiology of EBV and its association with malignant disease, Cambridge University.
16. 16. Imai S, Nishikawa J, Takada K. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. 1998 May;72(5):4371-8.
17. 17. Kelly GL, Milner AE, Baldwin GS. 2006. Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 40-103:14935.
18. 18. Kieff E, 1996. Epstein-Barr virus and its replication. In: Fields Virology. Fields BN, Knipe DM, Howley P et al., editors. Philadelphia, PA: Lippincott–Raven, pp. 2343–2396.
19. 19. Kitagawa N, Goto M, Kurozumi K. 2000. Epstein–Barr virus-encoded poly(A)(-) RNA supports Burkitt’s lymphoma growth through interleukin-10 induction. Embo J 50-19:6742.
20. 20. Klein E, Kis LL, Klein G. 2007. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions.Oncogene. 26:1297–1305.
21. 21. Li Y, Webster-Cyriaque J, Tomlinson C, Yohe M, Kenney S. 2004. Fatty acid synthase expression is induced by the Epstein–Barr virus immediate-early protein BRLF1 and required for lytic viral gene expression J. Virol. 78(8), in press.
22. 22. Liebowitz D, Kieff E. 1993. Epstein-Barr virus. In: The Human Herpesvirus. Roizman B, Whitley RJ, Lopez C, editors. New York. 107–172.
23. 23. Maeda E., Akahane M., Kiryu S., Kato N., Yoshikawa T., Hayashi N., Aoki S., Minami M., Fukayama H., Ohtomo K., 2009. Spectrum of Epstein-Barr virus-related diseases: a pictorial review 15: 8-12.
24. 24. Matsuura H, Austin N, Longnecker R, Theodore S. 2010. Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. PMID: 21149717.
25. 25. Miller G. 1990. The switch between latency and replication of Epstein-Barr virus. J Infect Dis. 44-161:833.
26. 26. Nanbo A, Yoshiyama H, Takada K. 2005. Epstein–Barr virus-encoded poly(A)- RNA confers resistance to apoptosis mediated through Fas by blocking the PKR pathway in human epithelial intestine 407 cells. J Virol 5-79:12280.
27. 27. Neri A, Barriga F, Inghirami G. 1991. Epstein–Barr virus infection precedes clonal expansion in Burkitt’s and acquired immunodeficiency syndromeassociated lymphoma. Blood 77:1092–5.
28. 28. Pagano JS, Blaser M, Buendia MA. 2004. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol 14:453–71.
29. 29. Rickinson AB., Young LS., Rowe M. 1987. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol, 61: 1310-1317. PMID:3033261.
30. 30. Sample JT., Sample CE. 2008. Epstein-Barr Virus: Molecular Biology. In: Encyclopedia of Virology. Mahy BWJ, van Regenmortel MHV, editors. Oxford: Academic Press, pp 157-167.
31. 31. Sandlund JT, Murphy SB, Santana VM, Behm F, Jones D, Berard CW, Furman WL, Ribeiro R, Crist WM, Greenwald C, Chen G, Walter A, Pui CH, 2000. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
32. 32. Straus SE, Cohen JI, Tosato G and Meier J, 1993. Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management. Annals of Internal Medicine. 118:45-58.
33. 33. Tao Q, Robertson KD, Manns A. 1998. Epstein–Barr virus (EBV) in endemic Burkitt’s lymphoma: molecular analysis of primary tumor tissue. Blood 91:1373-81.
34. 34. Thompson MP, Kurzrock R, 2004. Epstein-Barr virus and cancer. 2004 Feb 1;10(3):803-21.
35. 35. Van den Bosch CA. 2004. Is endemic Burkitt’s lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol 5:738–46.
36. 36. Wang D, Liebowitz D, Kieff E. 1985. An EBV Membrane Protein Expressed in Immortalized Lymphocytes Transforms Established Rodent Cells. Cell. 43: 831-840.
37. 37. Wilson JB, Bell JL, Levine AJ. 1996. Expression of Epstein–Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. Embo J 26-15:3117.
38. 38. Xue SA, Labrecque LG, Lu QL 2002. Promiscuous expression of Epstein–Barr virus genes in Burkitt’s lymphoma from the central African country Malawi. Int J Cancer 43-99:635.
39. 39. Yavuz G, 2002. Burkitt lenfoması ve Türkiye, XII. 7. Türk Pediatrik Onkoloji Grubu Kongresi, Yu-varlak hücreli tümörler, 22-25 Mayıs, 2002, İstanbul, Kongre kitabı,42-49).
40. 40. Young LS., Rickinson AB. 2004. Epstein-Barr Virus: 40 Years On. Nature Reviews. 4:757-768.
41. 41. Young, L, Alfieri C, Hennessy K, Evans H, O'Hara C, Kenneth C, Ritz J, Shapiro D, Rickinson A, Kieff E, Cohen JI, 1989. Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative Disease. New England Journal of Medicine. 321:1080-1085.